title: Drug and vaccine development for infectious diseases: the value of priority review vouchers.
authors.affiliation: Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. jmatheny@jhsph.edu
authors.forename: J
authors.initials: J
authors.lastname: Matheny
authors.forename: B
authors.initials: B
authors.lastname: Smith
authors.forename: B
authors.initials: B
authors.lastname: Courtney
authors.forename: M
authors.initials: M
authors.lastname: Mair
mesh_terms: D000890:Anti-Infective Agents / Q000191:economics; D003140:Communicable Disease Control / Q000191:economics / Q000458:organization & administration*; D017277:Drug Approval / Q000458:organization & administration; D055808:Drug Discovery / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D005380:Financing, Government / Q000458:organization & administration*; D006292:Health Priorities / Q000458:organization & administration; D006801:Humans; D014481:United States; D014483:United States Dept. of Health and Human Services; D014486:United States Food and Drug Administration / Q000458:organization & administration; D014612:Vaccines / Q000191:economics
chemical_list: D000890:Anti-Infective Agents; D014612:Vaccines